When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Porphyria cutanea tarda

Última revisión: 30 Apr 2025
Última actualización: 31 Aug 2022

Resumen

Definición

Anamnesis y examen

Principales factores de diagnóstico

  • blistering skin lesions
Todos los datos

Otros factores de diagnóstico

  • skin hyperpigmentation
  • hypertrichosis
  • scarring alopecia
  • red urine
Todos los datos

Factores de riesgo

  • male, middle-aged, white people
  • alcohol use
  • smoking
  • estrogen therapy
  • hepatitis C
  • HIV
  • hereditary hemochromatosis gene (HFE) mutation
  • uroporphyrinogen decarboxylase (UROD) mutations
  • exposure to halogenated polycyclic aromatic hydrocarbons
  • reduced levels of antioxidants
  • end-stage renal disease
  • diabetes mellitus
Todos los datos

Pruebas diagnósticas

Primeras pruebas diagnósticas para solicitar

  • plasma total porphyrins
  • plasma fluorescence emission
  • urinary total porphyrins
  • erythrocyte total porphyrins
Todos los datos

Pruebas diagnósticas que deben considerarse

  • fractionation of plasma porphyrins by high-performance liquid chromatography (HPLC)
  • fractionation of urinary porphyrins by HPLC
  • erythrocyte uroporphyrinogen decarboxylase (UROD) activity
  • fecal porphyrins
  • DNA studies
  • Liver function tests
  • serum ferritin
  • liver biopsy
  • skin biopsy
  • serum HIV enzyme-linked immunosorbent assay
  • serum hepatitis C surface antibodies
  • creatinine
  • BUN
  • hematocrit
  • hemoglobin
Todos los datos

Algoritmo de tratamiento

Agudo

no phlebotomy contraindications

phlebotomy contraindicated or poorly tolerated

En curso

relapse after remission

Colaboradores

Autores

Gagan Sood, MD

Associate Professor

Department of Medicine and Surgery

Baylor College of Medicine

Houston

TX

Divulgaciones

GS is an author of a number of references cited in this topic.

Karl E. Anderson, MD

Professor

Departments of Preventive Medicine and Community Health and Internal Medicine

University of Texas Medical Branch

Galveston

TX

Divulgaciones

KEA has received grants from the National Institutes of Health, the US Food and Drug Administration, and Alnylam Pharmaceuticals; he is an author of a number of references cited in this topic. KEA has received consulting fees, advisory board fees, and grants to the university from Alnylam Pharmaceuticals; consulting fees, advisory board fees, and grants from Recordati Rare Diseases; and consulting fees and grants from Mitsubishi Tanabe Pharma America.

Revisores por pares

Robert S. Dawe, MBChB, MRCP(UK), MD(Glasgow)

Consultant Dermatologist

Honorary Clinical Senior Lecturer

Department of Dermatology

Ninewells Hospital & Medical School

Dundee

UK

Divulgaciones

RSD declares that he has no competing interests.

Jeffrey P. Callen, MD

Professor of Medicine (Dermatology)

University of Louisville

Louisville

KY

Divulgaciones

JPC declares that he has no competing interests.

Montgomery Bissell, MD

Professor and Chief

Gastroenterology

University of California

San Francisco

CA

Divulgaciones

MB declares that he has no competing interests.

Referencias

Nuestros equipos internos de evidencia y editoriales colaboran con colaboradores expertos internacionales y revisores pares para garantizar que brindemos acceso a la información más clínicamente relevante posible.

Artículos principales

Phillips JD, Bergonia HA, Reilly CA, et al. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci USA. 2007 Jan;104:5079-84.Texto completo  Resumen

Jalil S, Grady JJ, Lee C, et al. Associations among behavior-related susceptibility factors in porphyria cutanea tarda. Clin Gastroenterol Hepatol. 2010 Mar;8(3):297-302;e1.Texto completo  Resumen

Singal AK. Porphyria cutanea tarda: recent update. Mol Genet Metab. 2019 Nov;128(3):271-81. Resumen

Handler NS, Handler MZ, Stephany MP, et al. Porphyria cutanea tarda: an intriguing genetic disease and marker. Int J Dermatol. 2017 Jun;56(6):e106-17. Resumen

Artículos de referencia

Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad